Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
This could be a potential option for patients at our practice who are struggling with weight loss
Eli Lilly and Company, the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), has announced positive topline results from a phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes
For gymnema, cinnamon, and banaba, we hold insufficient reliable evidence to rate their effectiveness for diabetes, prediabetes, or metabolic syndromethe claims these ingredients are marketed for in this product
The electrolyte guide and fiber supplement guide address two of the most practically important nutritional supports during treatment
